KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

LIPANTHYL 300 MG CAPSULES

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

300 MG

 

GENERIC NAME:

FENOFIBRATE

 

MANUFACTURER:

LABOTATOIRE FOURNIER

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Hypertriglyceridemia

Hypercholesterolemia

Hyperlipidemia

 

SIDE EFFECTS:

Influenza syndrome

infections

pruritus

skin rash and/or urticaria

Agranulocytosis

alveolitis, allergic

cholecystitis

cholelithiasis

eczema

hepatotoxicity

musculoskeletal symptoms, such as myalgia

myasthenia

myositis

rhabdomyolysis

pancreatitis

thrombocytopenia

Dizziness

eye irritation

gastrointestinal symptoms, such as belching

constipation

flatulence

libido, decreased

photosensitivity

rhinitis

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Renal function impairment, moderate

 

ADULT DOSE:

Antihyperlipidemic- Oral, initially, 67 mg per day, depending on the physician's assessment of the patient's risk for pancreatitis . Dosage should be individualized according to patient response, and should be increased sequentially, if necessary, following repeat serum triglyceride estimations at 4- to 8-week intervals . Fenofibrate should be discontinued in patients who do not have an adequate response after two months of treatment with the maximum recommended dose (201 mg per day) . In patients with impaired renal function, treatment should be initiated at a dose of 67 mg per day and increased only after the effects of fenofibrate on renal function and triglyceride concentrations have been evaluated .

 

MAXIMUM ADULT DOSE:

201 mg per day .

 

PEDIATRIC DOSE:

Safety and efficacy have not been established .  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Antihyperlipidemic- Oral, initially, 67 mg per day . See Usual adult dose .

 

 

PREVIOUS

  

NEXT